Optos’s “Buy” Rating Reaffirmed at Nplus1 Brewin (OPTS)
Optos (LON:OPTS)‘s stock had its “buy” rating reaffirmed by equities researchers at Nplus1 Brewin in a research report issued on Tuesday, Analyst Ratings Network reports. They currently have a GBX 260 ($4.27) price target on the stock. Nplus1 Brewin’s price target would indicate a potential upside of 32.15% from the company’s current price.
Optos (LON:OPTS) traded down 1.62% during mid-day trading on Tuesday, hitting GBX 196.75. 34,085 shares of the company’s stock traded hands. Optos has a 52 week low of GBX 106.75 and a 52 week high of GBX 221.00. The stock has a 50-day moving average of GBX 192.5 and a 200-day moving average of GBX 164.4. The company’s market cap is £142.1 million.
A number of other analysts have also recently weighed in on OPTS. Analysts at Jefferies Group raised their price target on shares of Optos from GBX 220 ($3.61) to GBX 230 ($3.78) in a research note to investors on Tuesday. They now have a “buy” rating on the stock. Separately, analysts at N+1 Singer reiterated a “buy” rating on shares of Optos in a research note to investors on Tuesday. They now have a GBX 260 ($4.27) price target on the stock. Finally, analysts at Panmure Gordon raised their price target on shares of Optos from GBX 206 ($3.38) to GBX 235 ($3.86) in a research note to investors on Friday. They now have a “buy” rating on the stock. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of GBX 252.67 ($4.15).
Optos Plc is a retinal imaging company. The Company’s medical devices produce ultra-widefield, high resolution digital images of approximately 82% of the retina in a single capture.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.